Cytomegalovirus vaccine: Phase II clinical trial results

Clinical Microbiology and Infection

Volumn 20, Issue S5, 2014, Pages 95-102

  Rieder, F ^a   Steininger, C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cytomegalovirus; Glycoproteins; Human immunodeficiency virus; Immunology; Intrauterine infection; Pentameric complex; Transplantation; Vaccine

Indexed keywords

ASP 0113; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN B MF59 VACCINE; IMMUNOLOGICAL ADJUVANT; MIFAMURTIDE; TOWNE VACCINE; UNCLASSIFIED DRUG; VCP260 VACCINE;

ANTIBODY TITER; ANTIVIRAL THERAPY; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; GRAFT RECIPIENT; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; VIREMIA; VIRUS TRANSMISSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; IMMUNOLOGY; NORMAL HUMAN; PREGNANCY; VACCINATION;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

CLINICAL TRIALS, PHASE II AS TOPIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOCOMPROMISED HOST; POSTPARTUM PERIOD; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANT RECIPIENTS; VACCINATION; VIREMIA;

EID: 84897480893     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12449     Document Type: Review

References (42)

1. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17: 253-276.
2. Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 2005; 5: 70.
3. Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect 2007; 13: 953-963.
4. Bowen EF, Griffiths PD, Davey CC, Emery VC, Johnson MA. Lessons from the natural history of cytomegalovirus. AIDS 1996; 10 (Suppl 1): S37-S41.
5. Laurenti L, Piccioni P, Cattani P et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004; 89: 1248-1252.
6. Limaye AP, Boeckh M. CMV in critically ill patients: pathogen or bystander? Rev Med Virol 2010; 20: 372-379.
7. Griffiths PD. CMV vaccine trial endpoints. J Clin Virol 2009; 46 (Suppl 4): S64-S67.
8. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 2004; 145: 485-491.
9. Steininger C. Novel therapies for cytomegalovirus disease. Recent Pat Anti-Infect Drug Discovery 2007; 2: 53-72.
10. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant 2013; 13 (Suppl 3): 24-40.
11. Griffiths PD, Stanton A, McCarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011; 377: 1256-1263.
12. Kharfan-Dabaja MA, Boeckh M, Wilck MB et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12: 290-299.
13. Pass RF. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol 2009; 46 (Suppl 4): S73-S76.
14. Pass RF, Duliege AM, Boppana S et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180: 970-975.
15. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002; 21: 133-138.
16. Frey SE, Harrison C, Pass RF et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999; 180: 1700-1703.
17. Jacobson MA, Adler SP, Sinclair EA et al. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 2009; 27: 1540-1548.
18. Heineman TC, Schleiss M, Bernstein DI et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006; 193: 1350-1360.
19. Bernstein DI, Reap EA, Katen K et al. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009; 28: 484-493.
20. La Rosa C, Longmate J, Lacet SF et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012; 205: 1294-1304.
21. Adler SP, Plotkin SA, Gonczol E et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999; 180: 843-846.
22. Berencsi K, Gyulai Z, Gönczöl E et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001; 183: 1171-1179.
23. Bernstein DI, Scleiss MR, Berencsi K et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 2002; 185: 686-690.
24. Sabbaj S, Pass RF, Goepfert PA, Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 2011; 203: 1534-1541.
25. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289: 1008-1011.
26. Zhang C, Pass RF. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine. Vaccine 2004; 23: 507-510.
27. Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect 2000; 125: 635-650.
28. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis 2007; 7: 71.
29. Plotkin SA, Higgins R, Kurtz JB et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58: 1176-1178.
30. Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001; 19: 1356-1362.
31. Walter S, Atkinson C, Sharland M et al. Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss. Arch Dis Child Fetal Neonatal Ed 2008; 93: F280-F285.
32. Kimberlin DW, Lin CY, Sanchez PJ et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143: 16-25.
33. Plotkin SA, Starr SE, Friedman HM et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991; 114: 525-531.
34. Adler SP, Starr SE, Plotkin SA et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995; 171: 26-32.
35. Steininger C, Kundi M, Kletzmayr J, Aberle SW, Popow-Kraupp T. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190: 1908-1912.
36. Wloch MK, Smith LR, Boutsaboualoy S et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008; 197: 1634-1642.
37. Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005; 79: 10330-10338.
38. Lilleri D, Kabanova A, Revello MG et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS ONE 2013; 8: e59863.
39. + T cell epitope recognition paradigms. Science 2013; 340: 1237874.
40. Loomis RJ, Lilja AE, Monroe J et al. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 2013; 31: 919-926.
41. Fu TM, Wang D, Freed DC et al. Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 2012; 30: 7469-7474.
42. Slavuljica I, Busche A, Babic M et al. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest 2010; 120: 4532-4545.